Maribavir
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Maribavir |
| DrugBank ID | DB06234 |
| Brand Names (EU) | Livtencity |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 87.79% |
Approved Indication (EMA)
LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bronchitis | 87.79% | DL |
| 2 | severe nonproliferative diabetic retinopathy | 79.11% | DL |
| 3 | bronchial neoplasm (disease) | 77.78% | DL |
| 4 | diabetic retinopathy | 76.24% | DL |
| 5 | filariasis | 74.26% | DL |
| 6 | rectosigmoid junction neoplasm | 73.41% | DL |
| 7 | colonic lymphangioma | 73.32% | DL |
| 8 | lipoma of colon | 73.23% | DL |
| 9 | cecum neuroendocrine tumor G1 | 73.13% | DL |
| 10 | cecum villous adenoma | 73.07% | DL |
| 11 | cecal disease | 73.07% | DL |
| 12 | colonic neoplasm | 72.96% | DL |
| 13 | cavernous hemangioma of colon | 72.95% | DL |
| 14 | colon leiomyoma | 72.94% | DL |
| 15 | benign neoplasm of cecum | 72.92% | DL |
| 16 | indolent plasma cell myeloma | 72.73% | DL |
| 17 | dermatitis | 72.65% | DL |
| 18 | plasma cell myeloma | 72.38% | DL |
| 19 | diabetic cataract | 71.82% | DL |
| 20 | ductal or ductular proliferation | 71.70% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.